PHVS Pharvaris NV

Pharvaris to Present at the GA²LEN UCARE Conference 2023

Pharvaris to Present at the GA²LEN UCARE Conference 2023

ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of one abstract for oral presentation and two abstracts for poster presentation at the GA²LEN UCARE Conference 2023, to be held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil.

Presentation details:

  • Title: Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase2 Trial Results

    Presenter: Markus Magerl, M.D.

    Date/Time: Friday, December 8, 11:18-11:26 a.m. BST (9:18-9:26 a.m. EST)

    Presentation Code: O07

    Type: Oral Presentation



  • Title: Analyzing Symptom Relief Definitions in HAE Using AMRA and PGI-C/PGI-S

    Presenter: Danny M. Cohn, M.D.

    Date/Time: Friday, December 8, 7:00-8:00 p.m. BST (5:00-6:00 p.m. EST)

    Presentation Code: P080

    Type: Happy Poster Hour Presentation



  • Title: Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant

    Presenter: Marcus Maurer, M.D.

    Date/Time: Friday, December 8, 7:00-8:00 p.m. BST (5:00-6:00 p.m. EST)

    Presentation Code: P081

    Type: Happy Poster Hour Presentation

Pharvaris is a bronze level sponsor of the GA²LEN UCARE Conference 2023. Following the close of the respective sessions, the presentation slides and posters will be made available on the Investors section of the Pharvaris website at: .

About Pharvaris

Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit .



Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
EN
30/11/2023

Underlying

PHVSPharvaris NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharvaris NV

Guy Sips ... (+6)
  • Guy Sips
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
HEIA HEINEKEN NV
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
RAND RANDSTAD NV
LOTB LOTUS BAKERIES NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ALFEN ALFEN NV
PHVS PHARVARIS NV
02/11/26 February 11, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
PHVS PHARVARIS NV

Pharvaris To present clinical data at the AAAAI 2026

Pharvaris will present multiple datasets at AAAAI 2026, including topline RAPIDe-3 results, final CHAPTER-1 data, supporting evidence for the extended-release formulation, AMRA endpoint validation, and results from a new kinin biomarker assay. We look forward to the prophylactic phase 3 (CHAPTER-3) readout in 3Q26 and reiterate our Buy and $ 36 TP.

02/11/26 February 11, 2026 1 EN
 PRESS RELEASE
Free
PHVS PHARVARIS NV

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for p...

February 10, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
PHVS PHARVARIS NV

Pharvaris Business update narrows topline prophylactic phase 3 data to...

Pharvaris provided a business update, which comes with narrowed guidance for the topline data from the phase 3 (CHAPTER-3) trial of deucrictibant in HAE prophylaxis, now expected in 3Q26 (previously 2H26). We're confident going into this readout, which we believe has a high probability of success based on the strong efficacy shown in phase 2. With the NDA filing in the on-demand setting on track for 1H26, and another phase 3 ongoing in AAE-C1INH, the product is set to address the broadest group ...

01/13/26 January 13, 2026 1 EN
Jacob Mekhael ... (+4)
  • Jacob Mekhael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Wim Hoste
GBLB GROUPE BRUXELLES LAMBERT SA
UCB UCB S.A.
ONTEX ONTEX GROUP N.V.
ARGX ARGEN-X SE
AUTL AUTOLUS THERAPEUTICS ADS
PHVS PHARVARIS NV
MDXH MDXHEALTH
01/13/26 January 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch